AMF Tjanstepension AB Increases Stock Position in Zoetis Inc. (NYSE:ZTS)

AMF Tjanstepension AB lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 23.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 105,376 shares of the company’s stock after acquiring an additional 20,001 shares during the period. AMF Tjanstepension AB’s holdings in Zoetis were worth $20,594,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Webster Bank N. A. lifted its holdings in shares of Zoetis by 89.1% during the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after purchasing an additional 82 shares during the period. Quarry LP lifted its holdings in shares of Zoetis by 273.2% during the second quarter. Quarry LP now owns 209 shares of the company’s stock worth $36,000 after purchasing an additional 153 shares during the period. Neo Ivy Capital Management acquired a new stake in shares of Zoetis during the fourth quarter worth $40,000. LRI Investments LLC acquired a new stake in Zoetis in the first quarter valued at $43,000. Finally, Hazlett Burt & Watson Inc. lifted its holdings in Zoetis by 60.7% in the first quarter. Hazlett Burt & Watson Inc. now owns 270 shares of the company’s stock valued at $46,000 after acquiring an additional 102 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Trading Down 1.0 %

Zoetis stock opened at $192.49 on Thursday. The stock has a market cap of $87.83 billion, a PE ratio of 37.09, a P/E/G ratio of 2.99 and a beta of 0.88. The stock has a 50-day moving average price of $186.89 and a 200 day moving average price of $175.21. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. The firm had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm’s quarterly revenue was up 8.3% compared to the same quarter last year. During the same quarter last year, the business posted $1.41 EPS. Equities research analysts predict that Zoetis Inc. will post 5.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of recent analyst reports. Argus raised Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Stifel Nicolaus raised their target price on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Piper Sandler raised their target price on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Finally, BTIG Research raised their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a report on Monday, August 12th. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $220.38.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.